PPCA 03
Alternative Names: PPCA-03Latest Information Update: 03 Oct 2024
At a glance
- Originator Immorta Bio
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ischaemia
Most Recent Events
- 11 Sep 2024 Preclinical trials in Ischaemia in USA (Parenteral) prior to September 2024 (Immorta Bio pipeline, September 2024)